MAHWAH, N.J., March 23, 2012 /PRNewswire/ -- HepatoChem, Inc, a
chemistry-based technology platform company with a primary focus on
metabolite production from bioactive small molecules, and an
investment holding of Heartland Bridge Capital, Inc. (OTCBB: HLBC),
announced that it will present at the Early-Stage Life Sciences
Technology Conference VIII at the Merck Research Laboratories in
Boston, MA, on April 12, 2012.
The Early-Stage Life Sciences Technology Conference will
showcase 20 life sciences technologies developed at the
universities, research institutions, and hospitals of Massachusetts and recently formed Massachusetts companies to an audience of
angel investors, venture capitalists and corporate investors.
www.mattcenter.org/lsconf2012/
HepatoChem recently moved to its new laboratory in Beverly, MA. This is an important step
for HepatoChem, which is committed to offering unique metabolite
production services. This laboratory is part of the
NorthShore Biotech Innoventure.
About HepatoChem, Inc
HepatoChem is a chemistry-based technology platform company with
a primary focus on metabolite production from bioactive small
molecules. Founded by Marc
Bazin, previously with Pfizer, Inc., and Prof. John T. Groves, the Hugh Stott Taylor Chair of
Chemistry at Princeton University,
HepatoChem is dedicated to developing technologies that help
pharmaceutical companies improve the quality of drug development
pipelines. HepatoChem offers a unique and powerful solution
to resolve the traditional lack of rapid and efficient metabolite
access in drug discovery. www.hepatochem.com
About Heartland Bridge Capital, Inc.
Heartland Bridge Capital, Inc. (OTCBB:HLBC) is a public company
that, in addition to managing its own operating entities,
participates in emerging companies run by exceptionally talented
entrepreneurs and operating executives who are dedicated to
creating positive change in our world. HLBC functions as an
owner, product developer, and investor focused primarily on
providing equity, acquisition debt, or bridge financing to emerging
high-growth companies and entrepreneurs in the areas of clean
energy, waste management, and life sciences.
www.heartlandbridgecapital.com.
To request an investor packet, or to receive updates on
Heartland Bridge Capital register online at
www.wallstreetnewscast.com/request/hlbc.html
Safe Harbor Notice
Certain statements contained herein are "forward-looking
statements" (as defined in the Private Securities Litigation Reform
Act of 1995). Heartland Bridge Capital, Inc. cautions that
statements made in this news release relating to the investment in
HepatoChem, and potential investment in and the business direction
of the Company, constitute forward-looking statements and makes no
guarantee of future performance. Forward-looking statements
are based on estimates and opinions of management at the time
statements are made. These statements may address issues that
involve significant risks, uncertainties, estimates, and
assumptions made by management. Actual results could differ
materially from current projections or implied results.
Heartland Bridge Capital, Inc. undertakes no obligation to
revise these statements following the date of this news
release.
Contact:
Melissa J. Diaz
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com
SOURCE HepatoChem, Inc; Heartland Bridge Capital, Inc.